NCT01332721 2018-12-05Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is IndicatedTracon Pharmaceuticals Inc.Phase 1 Completed38 enrolled 8 charts